Revealed…
Editor’s Note: At The Last Drop Summit we’re always looking out for special opportunities we believe you, as a valued subscriber, will want to see. Below you’ll find one from our partners at Behind the Markets. Please note that their opinions may differ from ours. Jeff Bezos backs tiny biotech with $130 mil investment Dear Reader, A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda. And they have a clean balance sheet with over $1 billion in cash to fund their efforts. Now, investors are lining up to buy shares. Stock purchases by institutional buyers more than doubled in the last quarter of 2023. What is it about this stock that has everyone excited? Find out more here >>> "The Buck Stops Here," Dylan Jovine, CEO & Founder
Behind the Markets | |
© 2024 Paradigm Press, LLC. 1001 Cathedral Street, Baltimore, MD 21201. By submitting your email address, you consent to Paradigm Press, LLC. delivering daily email issues and advertisements. To end your The Last Drop Summit e-mail subscription and associated external offers sent from The Last Drop Summit, feel free to click here. Please note: the mailbox associated with this email address is not monitored, so do not reply to this message. We welcome comments or suggestions at feedback@paradigmpressgroup.com. This address is for feedback only. For questions about your account or to speak with customer service, contact us here or call (844)-731-0984. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized financial advice. We allow the editors of our publications to recommend securities that they own themselves. However, our policy prohibits editors from exiting a personal trade while the recommendation to subscribers is open. In no circumstance may an editor sell a security before subscribers have a fair opportunity to exit. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication. All other employees and agents must wait 24 hours after on-line publication or 72 hours after the mailing of a printed-only publication prior to following an initial recommendation. Any investments recommended in this letter should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. The Last Drop Summit is committed to protecting and respecting your privacy. We do not rent or share your email address. Please read our Privacy Statement. If you are having trouble receiving your The Last Drop Summit subscription, you can ensure its arrival in your mailbox by whitelisting The Last Drop Summit. | | |
No comments:
Post a Comment
Keep a civil tongue.